These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2291662)

  • 1. Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.
    Marchbanks CR; Mikolich DJ; Mayer KH; Zinner SH; Dudley MN
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1966-72. PubMed ID: 2291662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment.
    Van der Auwera P; Stolear JC; George B; Dudley MN
    Antimicrob Agents Chemother; 1990 Aug; 34(8):1491-7. PubMed ID: 2221856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral antacids on disposition of intravenous enoxacin.
    Nix DE; Lebsack ME; Chapelsky M; Sedman AJ; Busch J; Norman A
    Antimicrob Agents Chemother; 1993 Apr; 37(4):775-7. PubMed ID: 8494374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.
    Patel SS; Spencer CM
    Drugs; 1996 Jan; 51(1):137-60. PubMed ID: 8741236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral cimetidine or ranitidine on the pharmacokinetics of intravenous enoxacin.
    Misiak PM; Eldon MA; Toothaker RD; Sedman AJ
    J Clin Pharmacol; 1993 Jan; 33(1):53-6. PubMed ID: 8429114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetics of enoxacin.
    Nakamura S; Kurobe N; Sekine Y
    J Chemother; 1989 Jul; 1(4 Suppl):543-4. PubMed ID: 16312524
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1986; 14 Suppl 3():S203-8. PubMed ID: 3463543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Enoxacin concentration in seminal fluid, in prostate secretions and in prostatic adenoma tissue following oral administration or intravenous infusion].
    Naber KG; Sörgel F; Kees F; Schumacher H; Sigl G; Zürcher J; Berger S
    Infection; 1989; 17 Suppl 1():S30-6. PubMed ID: 2478481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.
    Dobbs BR; Gazeley LR; Stewart IA; Edwards IR
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():61-6. PubMed ID: 3162903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxacin: a new fluoroquinolone.
    Jaber LA; Bailey EM; Rybak MJ
    Clin Pharm; 1989 Feb; 8(2):97-107. PubMed ID: 2645085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of enoxacin into middle ear effusion.
    Sundberg L; Edén T
    Acta Otolaryngol; 1990; 109(5-6):438-43. PubMed ID: 2360450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxacin in urinary tract infections associated with gynecological diseases.
    De Cecco L; Leone M
    J Chemother; 1989 Jul; 1(4 Suppl):886-7. PubMed ID: 16312687
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical pharmacokinetics of enoxacin in subjects with renal or hepatic impairment.
    Novelli A; Reali EF; Amato M; Dami A; Fallani S; Periti P
    J Chemother; 1989 Jul; 1(4 Suppl):546-8. PubMed ID: 16312526
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship between enoxacin and ciprofloxacin plasma concentrations and theophylline disposition.
    Davis JD; Aarons L; Houston JB
    Pharm Res; 1994 Oct; 11(10):1424-8. PubMed ID: 7855046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of enoxacin and its oxometabolite after multiple oral dosing and penetration into prostatic tissue.
    Hamel B; Mottet N; Audran M; Costa P; Bressolle F
    J Antimicrob Chemother; 2000 Dec; 46(6):993-6. PubMed ID: 11102420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Henwood JM; Monk JP
    Drugs; 1988 Jul; 36(1):32-66. PubMed ID: 3063494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of enoxacin in elderly patients.
    Wise R; Baker SL; Misra M; Griggs D
    J Antimicrob Chemother; 1987 Mar; 19(3):343-50. PubMed ID: 3471751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.